Andrew Reidenbach

Dr. Andrew Reidenbach


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
GRGregory J. Raymond
Gregory J. Raymond
HZHien Tran Zhao
Hien Tran Zhao
BRBrent Race
Brent Race
LRLynne D. Raymond
Lynne D. Raymond
KWKatie Williams
Katie Williams
SVSonia M Vallabh
Sonia M Vallabh
Prion disease is a fatal, incurable neurodegenerative disease of humans and other mammals caused by conversion of cellular prion protein (PrP C ) into a self-propagating neurotoxic conformer (prions; PrP Sc ). Strong genetic proofs of concept support lowering PrP expression as a therapeutic strategy. Antisense oligonucleotides (ASOs) can provide a practical route to lowering 1 target mRNA in the brain, but their development for prion disease has been hindered by 3 unresolved issues from prior work: uncertainty about mechanism of action, unclear potential for efficacy against established prion infection, and poor tolerability of drug delivery by osmotic pumps. Here, we test ASOs delivered by bolus intracerebroventricular injection to intracerebrally prion-infected WT mice. Prophylactic treatments given every 2–3 months extended survival times 61%–98%, and a single injection at 120 days after infection, near the onset of clinical signs, extended survival 55% (87 days). In contrast, a nontargeting control ASO was ineffective. Thus, PrP lowering is the mechanism of action of ASOs effective against prion disease in vivo, and infrequent — or even single — bolus injections of ASOs can slow prion neuropathogenesis and markedly extend survival, even when initiated near clinical signs. These findings should empower development of PrP-lowering therapy for prion disease.

22 March 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
MMMeredith A. Mortberg
Meredith A. Mortberg
HZHien T. Zhao
Hien T. Zhao
ARAndrew Reidenbach
Andrew Reidenbach
JGJuliana E. Gentile
Juliana E. Gentile
EKEric Kuhn
Eric Kuhn
EMEric Vallabh Minikel
Eric Vallabh Minikel
Prion protein (PrP) concentration controls the kinetics of prion replication and is a genetically and pharmacologically validated therapeutic target for prion disease. In order to evaluate PrP concentration as a pharmacodynamic biomarker and assess its contribution to known prion disease risk factors, we developed and validated a plate-based immunoassay reactive for PrP across 6 species of interest and applicable to brain and cerebrospinal fluid (CSF). PrP concentration varied dramatically across different brain regions in mice, cynomolgus macaques, and humans. PrP expression did not appear to contribute to the known risk factors of age, sex, or common PRNP genetic variants. CSF PrP was lowered in the presence of rare pathogenic PRNP variants, with heterozygous carriers of P102L displaying 55%, and D178N just 31%, of the CSF PrP concentration of mutation-negative controls. In rodents, pharmacologic reduction of brain Prnp RNA was reflected in brain parenchyma PrP and, in turn in CSF PrP, validating CSF as a sampling compartment for the effect of PrP-lowering therapy. Our findings support the use of CSF PrP as a pharmacodynamic biomarker for PrP-lowering drugs and suggest that relative reduction from individual baseline CSF PrP concentration may be an appropriate marker for target engagement.

1 September 2020 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ARAndrew Reidenbach
Andrew Reidenbach
MMMichael F. Mesleh
Michael F. Mesleh
DCDominick Casalena
Dominick Casalena
SVSonia M Vallabh
Sonia M Vallabh
JDJayme L. Dahlin
Jayme L. Dahlin
EMEric Vallabh Minikel
Eric Vallabh Minikel
Prion disease is a rapidly progressive neurodegenerative disorder caused by misfolding and aggregation of the prion protein (PrP), and there are currently no therapeutic options. PrP ligands could theoretically antagonize prion formation by protecting the native protein from misfolding or by targeting it for degradation, but no validated small-molecule binders have been discovered to date. We deployed a variety of screening methods in an effort to discover binders of PrP, including 19F-observed and saturation transfer difference (STD) nuclear magnetic resonance (NMR) spectroscopy, differential scanning fluorimetry (DSF), DNA-encoded library selection, and in silico screening. A single benzimidazole compound was confirmed in concentration-response, but affinity was very weak (Kd > 1 mM), and it could not be advanced further. The exceptionally low hit rate observed here suggests that PrP is a difficult target for small-molecule binders. While orthogonal binder discovery methods could yield high affinity compounds, non-small-molecule modalities may offer independent paths forward against prion disease.

18 December 2019 in Biomolecules
Verified
Journal Article
Open access
PDF file
ARAndrew Reidenbach
Andrew Reidenbach
EMEric Vallabh Minikel
Eric Vallabh Minikel
HZHien T. Zhao
Hien T. Zhao
SGStacy Guzman
Stacy Guzman
ALAlison Leed
Alison Leed
SVSonia M Vallabh
Sonia M Vallabh
Antisense oligonucleotides (ASOs) designed to lower prion protein (PrP) expression in the brain through RNase H1-mediated degradation of PrP RNA are in development as prion disease therapeutics. ASOs were previously reported to sequence-independently interact with PrP and inhibit prion accumulation in cell culture, yet in vivo studies using a new generation of ASOs found that only PrP-lowering sequences were effective at extending survival. Cerebrospinal fluid (CSF) PrP has been proposed as a pharmacodynamic biomarker for trials of such ASOs, but is only interpretable if PrP lowering is indeed the relevant mechanism of action in vivo and if measurement of PrP is unconfounded by any PrP–ASO interaction. Here, we examine the PrP-binding and antiprion properties of ASOs in vitro and in cell culture. Binding parameters determined by isothermal titration calorimetry were similar across all ASOs tested, indicating that ASOs of various chemistries bind full-length recombinant PrP with low- to mid-nanomolar affinity in a sequence-independent manner. Nuclear magnetic resonance, dynamic light scattering, and visual inspection of ASO–PrP mixtures suggested, however, that this interaction is characterized by the formation of large aggregates, a conclusion further supported by the salt dependence of the affinity measured by isothermal titration calorimetry. Sequence-independent inhibition of prion accumulation in cell culture was observed. The inefficacy of non-PrP-lowering ASOs against prion disease in vivo may be because their apparent activity in vitro is an artifact of aggregation, or because the concentration of ASOs in relevant compartments within the central nervous system (CNS) quickly drops below the effective concentration for sequence-independent antiprion activity after bolus dosing into CSF. Measurements of PrP concentration in human CSF were not impacted by the addition of ASO. These findings support the further development of PrP-lowering ASOs and of CSF PrP as a pharmacodynamic biomarker.

7 November 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
ARAndrew Reidenbach
Andrew Reidenbach
EMEric Vallabh Minikel
Eric Vallabh Minikel
HZHien T Zhao
Hien T Zhao
SGStacy Guzman
Stacy Guzman
ALAlison Leed
Alison Leed
SVSonia M Vallabh
Sonia M Vallabh
Antisense oligonucleotides (ASOs) designed to lower prion protein (PrP) expression in the brain through RNAse H1-mediated degradation of PrP RNA are in development as prion disease therapeutics. ASOs were previously reported to sequence-independently interact with PrP and inhibit prion accumulation in cell culture, yetin vivostudies using a new generation of ASOs found that only PrP-lowering sequences were effective at extending survival. Cerebrospinal fluid (CSF) PrP has been proposed as a pharmacodynamic biomarker for trials of such ASOs, but is only interpretable if PrP lowering is indeed the relevant mechanism of actionin vivoand if measurement of PrP is unconfounded by any PrP-ASO interaction. Here we examine the PrP-binding and antiprion properties of ASOsin vitroand in cell culture. Binding parameters determined by isothermal titration calorimetry were similar across all ASOs tested, indicating that ASOs of various chemistries bind full-length recombinant PrP with low- to mid-nanomolar affinity in a sequence-independent manner. Nuclear magnetic resonance, dynamic light scattering, and visual inspection of ASO-PrP mixtures suggested, however, that this interaction is characterized by the formation of large aggregates, a conclusion further supported by the salt dependence of the affinity measured by isothermal titration calorimetry. Sequence-independent inhibition of prion accumulation in cell culture was observed. The inefficacy of non-PrP-lowering ASOs against prion diseasein vivomay be because their apparent activityin vitrois an artifact of aggregation, or because the concentration of ASOs in relevant compartments within the central nervous system (CNS) quickly drops below the effective concentration for sequence-independent antiprion activity after bolus dosing into CSF. ELISA-based measurements of PrP concentration in human CSF were not impacted by the addition of ASO. These findings support the further development of PrP-lowering ASOs and of CSF PrP as a pharmacodynamic biomarker.

24 July 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
SISumaiya Iqbal
Sumaiya Iqbal
WJWei Jiang
Wei Jiang
EHEric Hansen
Eric Hansen
TATonia Aristotelous
Tonia Aristotelous
SLShuang Liu
Shuang Liu
HSHolly Soutter
Holly Soutter
DNA-Encoded Library (DEL) technology allows the screening of millions, or even billions, of encoded compounds in a pooled fashion which is faster and cheaper than traditional approaches. These massive amounts of data related to DEL binders and not-binders to the target of interest enable Machine Learning (ML) model development and screening of large, readily accessible, drug-like libraries in an ultra-high-throughput fashion. Here, we report a comparative assessment of the DEL+ML pipeline for hit discovery using three DELs and five ML models (fifteen DEL+ML combinations using two different feature representations). Each ML model was used to screen a diverse set of drug-like compound collections to identify orthosteric binders of two therapeutic targets, Casein kinase 1𝛼/δ (CK1𝛼/δ). Overall, 10% and 94% of the predicted binders and not-binders were confirmed in biophysical assays, including two nanomolar binders (187 and 69.6 nM affinity for CK1𝛼 and CK1δ, respectively). Our study provides insights into the DEL+ML paradigm for hit discovery: the importance of an ensemble ML approach in identifying a diverse set of confirmed binders, the usefulness of large training data and chemical diversity in the DEL, and the significance of model generalizability over accuracy. We shared our results via an open-source repository for further use and development of similar efforts.